Substance p secretion by carcinoid tumours

  • Petr Skrabanek
  • Dermot Cannon
  • James Kirrane
  • David Powell
Article

Summary

In 3 patients with foregut and midgut carcinoid tumours, high levels of immunoreactive substance P (ISP) were demonstrated in the general circulation, in the tumour extracts, in the tumour tissue culture medium, and in venous effluents from tumour and from metastases. In one patient studied during an attack of the carcinoid syndrome, ISP level was higher than in the basal state. Since substance P (SP) can cause flushing, hypotension, tachycardia, increased intestinal motility, and broncho-constriction, it may contribute to the pathophysiology of the carcinoid syndrome. Plasma ISP may serve as a circulating tumour marked and the levels may be used to monitor the response to therapy.

Keywords

Carcinoid Tumour Motilin Carcinoid Syndrome Tumour Extract Midgut Carcinoid Tumour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Alumets, J., Hakanson, R., Ingemansson and Sundler, F. 1977. Substance P and 5-HT in granules isolated from an intestinal argentaffin carcinoid. Histochemistry 52, 217.PubMedCrossRefGoogle Scholar
  2. Amin, A. H., Crawford, T. B. B. and Gaddum, J. H. 1954. The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog. J. Physiol. 126, 596.PubMedGoogle Scholar
  3. Bhoola, K. D., Collier, H. O. J., Schachter, M. and Shorley, P. G. 1962. Actions of some peptides on bronchial muscle. 1962. Brit. J. Pharmacol. 19, 190.PubMedGoogle Scholar
  4. Bisset, G. W. and Lewis, G. P. 1962. A spectrum of pharmacological activity in some biologically active peptides. Brit. J. Pharmacol. 19, 168.PubMedGoogle Scholar
  5. Chang, M. M. and Leeman, S. E. 1970. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J. Biol. Chem. 245, 4784.PubMedGoogle Scholar
  6. Dalgliesh, C. E., Toh, C. C. and Work, T. S. 1953. Fractionation of the smooth muscle stimulants present in extracts of gastrointestinal tract. Identification of 5-hydroxytryptamine and its distinction from substance P. J. Physiol. 120, 298.PubMedGoogle Scholar
  7. Dunér, H. and Pernow, B. 1960. Circulatory studies on substance P in man. Acta Physiol. Scand. 49, 261.PubMedGoogle Scholar
  8. Erspamer, V. 1954. Pharmacology of indolealkylamines. Pharmacol. Rev. 6, 425.PubMedGoogle Scholar
  9. Erspamer, V. and Melchiorri, P. 1973. Active polypeptides of the amphibian skin and their synthetic analogues. Pure Appl. Chem. 35, 463.CrossRefGoogle Scholar
  10. Grahame-Smith, D. G. 1972. The Carcinoid Syndrome, London, Heinemann. p. 43.Google Scholar
  11. Hakanson, R., Bengmark, S., Brodin, E., Ingemansson, S., Larsson, L.-I., Nilsson, G. and Sundler, F. 1977. Substance P-like immunoreactivity in intestinal carcinoid tumours.in Substance P. ed. by U. S. von Euler and B. Pernow. New York, Raven Press. p. 55.Google Scholar
  12. Hallberg, D. and Pernow, B. 1975. Effect of substance P on various vascular beds in the dog. Acta Physiol. Scand. 93, 277.PubMedGoogle Scholar
  13. Heitz, P., Polak, J. M., Kasper, M., Timson, C. M. and Pearse, A. G. E. 1977. Immunoelectron cytochemical localization of motilin and substance P in rabbit bile duct enterochromaffin cells. Histochemistry 50, 319.PubMedCrossRefGoogle Scholar
  14. Inouye, A., Kataoka, K. and Shinagawa, Y. 1962. 5-hydroxytryptamine in the subcellular particles of rabbit brain. Nature 194, 286.CrossRefGoogle Scholar
  15. Johnson, A. R. and Erdös, E. G. 1973. Release of histamine from mast cells by vasoactive peptides. Proc. Soc. Exp. Biol. Med. 142, 1252.PubMedGoogle Scholar
  16. Lembeck, F. 1953. 5-hydroxytryptamine in a carcinoid tumour. Nature 172, 910.CrossRefGoogle Scholar
  17. Lembeck, F. 1954. Uber die Nachweis von 5-Oxytryptamin (Enteramin, Serotonin) in Carcinoidmetastasen. Nauyn-Schmiedeberg's Arch. Pharmakol. 221, 50.Google Scholar
  18. Lembeck, F., Popper, H. and Juan, H. 1976. Release of prostaglandins by bradykinin as an intrinsic mechanism of its algesic action. Naunyn-Schmiedeberg's Arch. Pharmakol. 294, 69.CrossRefGoogle Scholar
  19. Liljedahl, S. O., Mattson, O. and Pernow, B. 1958. Effect of substance P on intestinal motility in man. Scand. J. Clin. Lab. Invest. 10, 16.PubMedCrossRefGoogle Scholar
  20. Melchiorri, P., Tonelli, F. and Negri, L. 1977. Comparative circulatory effects of substance P. eledosin, and physalemin in the dog.in Substance P. ed. by U. S. von Euler and B. Pernow. New York, Raven Press. p. 311.Google Scholar
  21. O'Connell, R., Skrabanek, P., Cannon, D. and Powell, D. 1976. High-sensitivity radioimmunoassay for substance P. Ir. J. Med. Sci. 145, 392.PubMedGoogle Scholar
  22. Powell, D., Leeman, S., Tregear, G. W., Niall, H. D. and Potts, J. T. Jr. 1973. Radioimmunoassay for Substance P. Nature 241, 252.CrossRefGoogle Scholar
  23. Powell, D., Skrabanek, P. and Cannon, D. 1977. Substance P: Radioimmunoassay studies.in Substance P. ed. by U. S. von Euler and B. Pernow. New York, Raven Press, p. 35.Google Scholar
  24. Said, S. I. and Mutt, V. 1977. Relationship of spasmogenic and smooth muscle relaxant peptides from normal lung to other vasoactive peptides. Nature 265, 84.PubMedCrossRefGoogle Scholar
  25. Skrabanek, P., Cannon, D., Kirrane, J., Legge, D. and Powell, D. 1976. Circulating immunoreactive substance P in man. Ir. J. M. Sci. 145, 399.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • Petr Skrabanek
    • 1
  • Dermot Cannon
    • 1
  • James Kirrane
    • 1
  • David Powell
    • 1
  1. 1.Endocrine UnitMater Misericordiae HospitalDublin

Personalised recommendations